Abstract:Background. Multiple organ dysfunction syndrome (MODS) is the commonest cause of death in intensive care units. Growing recognition of this disease in the last 30 years may be due to advances in early resuscitation unmasking delayed sequelae in those who would have died previously. MODS occurs after shock of various etiologies, especially sepsis, and may be the result of overactivated systemic inflammation. As yet, therapies directed at preventing or improving MODS have not dramatically altered the outcomes. Phosphodiesterases (PDEs) are enzymes primarily responsible for the breakdown of the intracellular second messengers adenosine 3′,5′-cyclic monophosphate and guanosine 3′,5′-cyclic monophosphate. Although these enzymes were initially described many years ago, new families and subtypes of PDEs continue to be discovered. There is also a wide variation in the distribution of PDEs among tissues or species. This tissue-specific distribution has led to differential pharmacologic actions of PDE inhibitors. Experimental and clinical studies have demonstrated that PDE inhibition has beneficial effects on cytokine levels and tissue oxygenation, and hence on the morbidity and mortality of MODS. Methods. A systematic literature review was conducted to investigate the potential roles of multiple PDE families in the development of MODS. A text word search of PubMed was performed, followed by a further review of references from the initial citations. Results. Several PDE families are involved in inflammatory cell activation, cytokine production and dysfunction of the endothelial barrier, hemodynamics and metabolism in sepsis and MODS. Inhibitors of these PDEs suppress the release of multiple inflammatory mediators, including inflammatory cytokines, and improve the endothelial barrier, hemodynamics and metabolism. Conclusions. Certain PDEs are promising therapeutic targets for MODS. The role of PDE inhibitors in the treatment of MODS, whether as a primary or adjuvant therapy, remains to be investigated.

Potential Role of Reactive Oxygen Species in Pancreatitis-Associated Multiple Organ Dysfunction

Reactive Oxygen Species and Oxidative Stress in Acute Pancreatitis: Pathogenesis and New Therapeutic Interventions

Potential Role of Phosphodiesterases in the Development of Multiple Organ Dysfunction

Role of Mast Cells in the Development of Pancreatitis-Induced Multiple Organ Dysfunction

Nicotinamide adenine dinucleotide phosphate oxidase in pancreatic diseases: Mechanisms and future perspectives

Potential Factors of Interorgan Signals in the Development of Pancreatitis-Associated Acute Lung Injury and Acute Respiratory Distress Syndrome

Cellular and Molecular Events in Acute Pancreatitis

Role of Nuclear Factor-Kappab, Reactive Oxygen Species and Cellular Signaling in the Early Phase of Acute Pancreatitis.

Correlation of Nitric Oxide and Other Free Radicals with the Severity of Acute Pancreatitis and Complicated Systemic Inflammatory Response Syndrome

Antioxidant and Calcium Channel Blockers Counteract Endothelial Barrier Injury Induced by Acute Pancreatitis in Rats.

Acute Pancreatitis-Associated Lung Injury: Pathophysiological Mechanisms and Potential Future Therapies

Oxidative stress and acute pancreatitis (Review)

Role of oxygen-free radicals in enterocyte apoptosis and bacterial translocation in abdominal compartment syndrome:

Role of Macrophage Overactivation in the Development of Acute Pancreatic Injury in Rats

Antioxidant Therapy in Pancreatitis

ROS and diseases: role in metabolism and energy supply

Effects of Oxidative Stress on Serum Metabolism in Acute Pancreatitis Rats Based on Untargeted Metabolomics

Research progress of oxidative stress and acute pancreatitis

Protective Role of Reactive Oxygen Species in Endotoxin-Induced Lung Inflammation Through Modulation of IL-10 Expression

Antioxidant Therapy in Acute Pancreatitis: Experimental and Clinical Evidence

A New Understanding of Pancreatitis-Associated Pulmonary Injury